Fonterra sells DFE Pharma for $633m
Proceeds to go toward debt reduction.
Fonterra is selling its half share in Germany-based DFE Pharma for $633 million, allowing significant progress toward its debt reduction target.
The business will be sold to private equity funds run by CVC Capital Partners.
The proceeds comprise cash of $537m plus 15-year vendor finance of
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive FREE offer for uni students studying at a New Zealand university (valued at $499).
Individual
Group membership
NBR Marketplace
Smartphone Only Subscription
NZ$29.95 / monthly
Monthly Premium Online Subscription
NZ$49.95 / monthly
Smartphone Only Annual Subscription
NZ$299.00 / yearly
Yearly Premium Online Subscription
NZ$499.00 / yearly
Premium Group Membership 10 Users
NZ$385+GST / monthly
$38.5 per user - Pay by monthly
credit card debit
Premium Group Membership 20 Users
NZ$660+GST / monthly
$33 per user - Pay by monthly
credit card debit
Premium Group Membership 50 Users
NZ$1375+GST / monthly
$27.5 per user - Pay by monthly
credit card debit
Premium Group Membership 100 Users
NZ$2100+GST / monthly
$21 per user - Pay by monthly
credit card debit
Yearly Premium Online Subscription + NBR Marketplace
NZ$999.00 / yearly
Already have an account? Login
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.
